Interestingly, results from both technologies combined demonstrate that liquid biopsy is able to detect more HER2 positivity cases than the tissue-based approach; 11 patients had HER2+ CTCs detected (73.3%) as opposed to 4 patients that tested positive for HER2 in primary tumour tissue assessment (26.7%). Here, ERBB2 is linked to neoplasm.